eLearning module: Clinical development
In this expert authored eLearning module, Professor Huub Schellekens looks at the clinical development process of biosimilars, particularly the importance of clinical trials to demonstrate biosimilarity.
This module will take up to 20 minutes to complete.
Learning objectives
On completion of the eLearning module, you will be able to:
- Explain what is “Totality of Evidence” and why it is important to prove biosimilarity.
- Explain what type of clinical trials are important in the clinical development process of biosimilars and how they contribute to prove biosimilarity.
Target audience
All medical oncologists, specialist nurses, and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.
r Huub Schellekens MD, PhD is emeritus professor of Pharmaceutical Biotechnology at Utrecht University in the Netherlands. He studied medicine at Erasmus University in Rotterdam, The Netherlands ( 1967-1973), where he also did his training in Medical Microbiology (1976-1980) and received his PhD. in 1980.